Caspase-Glo 3/7 assay.

EN Erin Nolin
SG Sara Gans
LL Luis Llamas
SB Somnath Bandyopadhyay
SB Scott M. Brittain
PB Paula Bernasconi-Elias
KC Kyle P. Carter
JL Joseph J. Loureiro
JT Jason R. Thomas
MS Markus Schirle
YY Yi Yang
NG Ning Guo
GR Guglielmo Roma
SS Sven Schuierer
MB Martin Beibel
AL Alicia Lindeman
FS Frederic Sigoillot
AC Amy Chen
KX Kevin X. Xie
SH Samuel Ho
JR John Reece-Hoyes
WW Wilhelm A. Weihofen
KT Kayla Tyskiewicz
DH Dominic Hoepfner
RM Richard I. McDonald
NG Nicolette Guthrie
AD Abhishek Dogra
HG Haibing Guo
JS Jian Shao
JD Jian Ding
SC Stephen M. Canham
GB Geoff Boynton
EG Elizabeth L. George
ZK Zhao B. Kang
CA Christophe Antczak
JP Jeffery A. Porter
OW Owen Wallace
JT John A. Tallarico
AP Amy E. Palmer
JJ Jeremy L. Jenkins
RJ Rishi K. Jain
SB Simon M. Bushell
CF Christy J. Fryer
request Request a Protocol
ask Ask a question
Favorite

To assess if NVS-ZP7–1 was stimulating the activity of caspase 3/7, an indicator of apoptosis, the Caspase-Glo 3/7 assay system (Promega) was used. Included in this assay were control compounds including staurosporine (Calbiochem), which is known to induce apoptosis, along with negative controls that included DMSO and NVS-ZP7–2 (inactive version of NVS-ZP7–1). The T-ALL cell lines TALL-1 and SUPT11 were used for this assay. Cells (1 × 103) were plated into 384-well assay plates and treated with a 10 μM final concentration of compound. Caspase-Glo 3/7 reagent was prepared according to the Promega protocol and added to the cells 48 h after compound addition. Each sample was incubated with the Caspase-Glo 3/7 reagent for 45 min and then luminescence (relative luminescence units) was read out on the EnVision multilabel plate reader (PerkinElmer). Bar charts were then generated using the luminescence reads in GraphPad Prism.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A